Top 5 Stocks to Buy Now
→ The Treasury just bought its own debt (From Golden Portfolio) (Ad)tc pixel Free RAPP Stock Alerts

Rapport Therapeutics (RAPP) Competitors

Rapport Therapeutics logo
$40.02 +1.14 (+2.94%)
Closing price 03:59 PM Eastern
Extended Trading
$40.08 +0.05 (+0.13%)
As of 05:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

RAPP vs. SYRE, KYMR, PRAX, PCVX, and PTGX

Should you buy Rapport Therapeutics stock or one of its competitors? MarketBeat compares Rapport Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Rapport Therapeutics include Spyre Therapeutics (SYRE), Kymera Therapeutics (KYMR), Praxis Precision Medicines (PRAX), Vaxcyte (PCVX), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical products" industry.

How does Rapport Therapeutics compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and Rapport Therapeutics (NASDAQ:RAPP) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations and valuation.

Spyre Therapeutics has a beta of 3.05, suggesting that its share price is 205% more volatile than the broader market. Comparatively, Rapport Therapeutics has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market.

Rapport Therapeutics has lower revenue, but higher earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Rapport Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Spyre Therapeutics$890K8,414.70-$155.20M-$2.08N/A
Rapport TherapeuticsN/AN/A-$111.48M-$2.60N/A

In the previous week, Spyre Therapeutics had 5 more articles in the media than Rapport Therapeutics. MarketBeat recorded 10 mentions for Spyre Therapeutics and 5 mentions for Rapport Therapeutics. Rapport Therapeutics' average media sentiment score of 1.21 beat Spyre Therapeutics' score of 0.32 indicating that Rapport Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Spyre Therapeutics
3 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Rapport Therapeutics
3 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Spyre Therapeutics currently has a consensus target price of $95.83, indicating a potential upside of 11.12%. Rapport Therapeutics has a consensus target price of $57.86, indicating a potential upside of 44.56%. Given Rapport Therapeutics' higher possible upside, analysts clearly believe Rapport Therapeutics is more favorable than Spyre Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Spyre Therapeutics
1 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
2 Strong Buy rating(s)
3.00
Rapport Therapeutics
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.91

Rapport Therapeutics' return on equity of -24.78% beat Spyre Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Spyre TherapeuticsN/A -42.88% -27.76%
Rapport Therapeutics N/A -24.78%-23.44%

80.4% of Spyre Therapeutics shares are owned by institutional investors. 15.7% of Spyre Therapeutics shares are owned by company insiders. Comparatively, 12.5% of Rapport Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Spyre Therapeutics beats Rapport Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Rapport Therapeutics compare to Kymera Therapeutics?

Rapport Therapeutics (NASDAQ:RAPP) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Rapport Therapeutics has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 2.02, meaning that its stock price is 102% more volatile than the broader market.

Rapport Therapeutics presently has a consensus target price of $57.86, suggesting a potential upside of 44.56%. Kymera Therapeutics has a consensus target price of $117.14, suggesting a potential upside of 17.29%. Given Rapport Therapeutics' higher possible upside, equities research analysts plainly believe Rapport Therapeutics is more favorable than Kymera Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rapport Therapeutics
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.91
Kymera Therapeutics
1 Sell rating(s)
0 Hold rating(s)
21 Buy rating(s)
1 Strong Buy rating(s)
2.96

In the previous week, Kymera Therapeutics had 12 more articles in the media than Rapport Therapeutics. MarketBeat recorded 17 mentions for Kymera Therapeutics and 5 mentions for Rapport Therapeutics. Rapport Therapeutics' average media sentiment score of 1.21 beat Kymera Therapeutics' score of 0.17 indicating that Rapport Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Rapport Therapeutics
3 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Kymera Therapeutics
6 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Rapport Therapeutics has higher earnings, but lower revenue than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Rapport Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rapport TherapeuticsN/AN/A-$111.48M-$2.60N/A
Kymera Therapeutics$39.21M209.52-$311.35M-$3.57N/A

Rapport Therapeutics has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -611.94%. Kymera Therapeutics' return on equity of -24.71% beat Rapport Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Rapport TherapeuticsN/A -24.78% -23.44%
Kymera Therapeutics -611.94%-24.71%-22.05%

Summary

Kymera Therapeutics beats Rapport Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Rapport Therapeutics compare to Praxis Precision Medicines?

Rapport Therapeutics (NASDAQ:RAPP) and Praxis Precision Medicines (NASDAQ:PRAX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings.

Rapport Therapeutics presently has a consensus price target of $57.86, suggesting a potential upside of 44.56%. Praxis Precision Medicines has a consensus price target of $566.21, suggesting a potential upside of 83.28%. Given Praxis Precision Medicines' stronger consensus rating and higher probable upside, analysts clearly believe Praxis Precision Medicines is more favorable than Rapport Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rapport Therapeutics
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.91
Praxis Precision Medicines
2 Sell rating(s)
1 Hold rating(s)
14 Buy rating(s)
4 Strong Buy rating(s)
2.95

67.8% of Praxis Precision Medicines shares are owned by institutional investors. 12.5% of Rapport Therapeutics shares are owned by company insiders. Comparatively, 3.0% of Praxis Precision Medicines shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Rapport Therapeutics' return on equity of -24.78% beat Praxis Precision Medicines' return on equity.

Company Net Margins Return on Equity Return on Assets
Rapport TherapeuticsN/A -24.78% -23.44%
Praxis Precision Medicines N/A -43.02%-40.22%

Rapport Therapeutics has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.71, indicating that its stock price is 171% more volatile than the broader market.

Rapport Therapeutics has higher earnings, but lower revenue than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Rapport Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rapport TherapeuticsN/AN/A-$111.48M-$2.60N/A
Praxis Precision Medicines$8.55M1,007.40-$303.27M-$13.37N/A

In the previous week, Praxis Precision Medicines had 3 more articles in the media than Rapport Therapeutics. MarketBeat recorded 8 mentions for Praxis Precision Medicines and 5 mentions for Rapport Therapeutics. Rapport Therapeutics' average media sentiment score of 1.21 beat Praxis Precision Medicines' score of 0.66 indicating that Rapport Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Rapport Therapeutics
3 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Praxis Precision Medicines
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Praxis Precision Medicines beats Rapport Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Rapport Therapeutics compare to Vaxcyte?

Rapport Therapeutics (NASDAQ:RAPP) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Rapport Therapeutics presently has a consensus target price of $57.86, suggesting a potential upside of 44.56%. Vaxcyte has a consensus target price of $86.00, suggesting a potential upside of 59.64%. Given Vaxcyte's higher probable upside, analysts plainly believe Vaxcyte is more favorable than Rapport Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rapport Therapeutics
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.91
Vaxcyte
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63

Rapport Therapeutics' return on equity of -24.78% beat Vaxcyte's return on equity.

Company Net Margins Return on Equity Return on Assets
Rapport TherapeuticsN/A -24.78% -23.44%
Vaxcyte N/A -32.51%-29.51%

Rapport Therapeutics is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rapport TherapeuticsN/AN/A-$111.48M-$2.60N/A
VaxcyteN/AN/A-$766.63M-$6.88N/A

In the previous week, Vaxcyte had 10 more articles in the media than Rapport Therapeutics. MarketBeat recorded 15 mentions for Vaxcyte and 5 mentions for Rapport Therapeutics. Rapport Therapeutics' average media sentiment score of 1.21 beat Vaxcyte's score of 0.45 indicating that Rapport Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Rapport Therapeutics
3 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Vaxcyte
7 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Rapport Therapeutics has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market.

96.8% of Vaxcyte shares are held by institutional investors. 12.5% of Rapport Therapeutics shares are held by insiders. Comparatively, 3.3% of Vaxcyte shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Rapport Therapeutics beats Vaxcyte on 9 of the 14 factors compared between the two stocks.

How does Rapport Therapeutics compare to Protagonist Therapeutics?

Protagonist Therapeutics (NASDAQ:PTGX) and Rapport Therapeutics (NASDAQ:RAPP) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.

Protagonist Therapeutics presently has a consensus price target of $115.21, indicating a potential downside of 5.68%. Rapport Therapeutics has a consensus price target of $57.86, indicating a potential upside of 44.56%. Given Rapport Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Rapport Therapeutics is more favorable than Protagonist Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Protagonist Therapeutics
1 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.88
Rapport Therapeutics
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.91

Rapport Therapeutics has lower revenue, but higher earnings than Protagonist Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Rapport Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Protagonist Therapeutics$46.02M170.70-$130.15M-$1.81N/A
Rapport TherapeuticsN/AN/A-$111.48M-$2.60N/A

Rapport Therapeutics has a net margin of 0.00% compared to Protagonist Therapeutics' net margin of -154.88%. Protagonist Therapeutics' return on equity of -17.76% beat Rapport Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Protagonist Therapeutics-154.88% -17.76% -16.47%
Rapport Therapeutics N/A -24.78%-23.44%

Protagonist Therapeutics has a beta of 1.85, meaning that its stock price is 85% more volatile than the broader market. Comparatively, Rapport Therapeutics has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market.

98.6% of Protagonist Therapeutics shares are held by institutional investors. 5.2% of Protagonist Therapeutics shares are held by company insiders. Comparatively, 12.5% of Rapport Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Protagonist Therapeutics had 1 more articles in the media than Rapport Therapeutics. MarketBeat recorded 6 mentions for Protagonist Therapeutics and 5 mentions for Rapport Therapeutics. Rapport Therapeutics' average media sentiment score of 1.21 beat Protagonist Therapeutics' score of 1.09 indicating that Rapport Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Protagonist Therapeutics
5 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Rapport Therapeutics
3 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Protagonist Therapeutics beats Rapport Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Rapport Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RAPP and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RAPP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RAPP vs. The Competition

Export
MetricRapport TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.86B$3.49B$6.54B$12.32B
Dividend YieldN/A2.28%2.68%5.88%
P/E Ratio-15.3911.3421.4322.01
Price / SalesN/A328.65530.17107.90
Price / CashN/A130.9645.2953.76
Price / Book3.948.2610.766.41
Net Income-$111.48M$23.91M$3.56B$337.14M
7 Day Performance8.55%3.05%1.37%-0.48%
1 Month Performance6.11%2.40%0.81%0.49%
1 Year Performance223.30%56.35%30.53%28.16%

Rapport Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RAPP
Rapport Therapeutics
3.1913 of 5 stars		$40.02
+2.9%		$57.86
+44.6%		+257.4%$1.86BN/AN/AN/A
SYRE
Spyre Therapeutics
1.6831 of 5 stars		$83.41
-0.2%		$94.17
+12.9%		+561.1%$7.24B$890KN/A73
KYMR
Kymera Therapeutics
2.0021 of 5 stars		$87.44
+2.2%		$117.14
+34.0%		+112.2%$7.19B$39.21MN/A170
PRAX
Praxis Precision Medicines
2.9918 of 5 stars		$257.25
-2.8%		$572.72
+122.6%		+633.5%$7.17B$8.55MN/A110
PCVX
Vaxcyte
2.6703 of 5 stars		$49.31
-0.5%		$86.00
+74.4%		+56.3%$7.12BN/AN/A160

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:RAPP) was last updated on 6/24/2026 by MarketBeat.com Staff.
From Our Partners
Firm That Predicted 2008, 2020, 2022: Right Now Looks Worse
The firm that predicted the dot-com crash, the 2008 financial crisis, the 2020 COVID crash, and the 2022 bear ...
TradeSmith | Sponsoredtc pixel
The Treasury just bought its own debt
On April 16th, the U.S. Treasury executed a $15 billion buyback of its own debt - the largest in history - whi...
Golden Portfolio | Sponsoredtc pixel
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely, LLC | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Elon Is Quietly Doubling Down on This Bizarre Asset
Yahoo Finance reports this technology 'May Unlock $400 Trillion' - and Bloomberg calls it 'unavoidable.' Elon ...
Brownstone Research | Sponsoredtc pixel
VWAV: An Under-the-Radar Defense Play
VisionWave Holdings (NASDAQ: VWAV) is developing a multi-domain defense platform combining AI-powered analytic...
Equiscreen | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel